Drug Profile
Research programme: T-cell receptor immunotherapies - Medigene/Regeneron Pharmaceuticals
Alternative Names: MAGE-A4 TCR - bluebird bio/Medigene; TCR immunotherapies - bluebird bio/MedigeneLatest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator MediGene AG
- Developer bluebird bio; MediGene AG
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Apr 2024 Regeneron Pharmaceuticals acquires T-cell receptor immunotherapies from 2seventy bio
- 30 Jan 2024 Regeneron plans to Acquire T-cell receptor immunotherapies from 2seventy bio in the first half 2024
- 12 Sep 2023 JW Therapeutics intends to expand licensing agreement to add two new programmes for TCR based Solid tumours and CAR-T Autoimmune disorders